Biotech startup Nusantics, founded by Sharlini Eriza Putri, is one of Indonesia's few genomics tech firms. The company changed course rapidly last year to produce Covid-19 testing kits when they were needed most. Here’s what they learned
Before the pandemic, Sharlini Eriza Putri’s genomics technology company, Nusantics, was focused solely on the field of microbiome analysis, which is the study of the genome of all microorganisms.
In March last year, as the Covid-19 pandemic hit Indonesia, Putri and her co-founders knew they could help. Within days, they had produced a Covid-19 testing kit and contacted the government to offer their assistance.
After making the first generation of testing kits pro bono, at a time when the shortage of testing was at its most critical, Nusantics now runs the testing kit arm of its business as a social enterprise, reducing the cost of a testing kit from 2.5 million Indonesian Rupiah (US$180) to 900,000 (US$65).
We talk to Putri about the power of the microbiome, the challenges of working with governments and why she doesn’t expect the pandemic to go away anytime soon.
What is microbiome profiling?
More than 50 percent of our body is actually the microbiome. Microbiomes are bacteria, fungi, fibres as well as archaea. They live inside our body, in our gut, in our skin, in our skull—everywhere. And the diversity of the microbiome really shapes our immunity. For example, the latest research shows that when the gut microbiome composition is unbalanced, the severity of Covid-19 patients’ condition is worrying compared to [those with a balanced microbiome]. As we know, there are some people who are infected with the Covid-19 virus but they seem perfectly well. It's because their gut microbiome is in perfect balance.